Contingency management for adherence to injectable medication for substance use disorders
- 21 June 2026
- journal article
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- Vol. 190, 210055
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Veterans Affairs
- Rehabilitation Research and Development Service (IK2RX003789)
This publication has 25 references indexed in Scilit:
- Contingency management for substance use disorders in the U.S. Veterans Health Administration: 2018–2022Journal of Substance Use and Addiction Treatment, 2024
- Feasibility, Acceptability, and Preliminary Efficacy of a Smartphone-Based Contingency Management Intervention for Buprenorphine AdherenceBehavior Analysis in Practice, 2022
- Contingency Management for Patients Receiving Medication for Opioid Use DisorderJAMA Psychiatry, 2021
- Comparison of Treatments for Cocaine Use Disorder Among AdultsJAMA Network Open, 2021
- Effect of Escalating and Deescalating Financial Incentives vs Usual Care to Improve Antidepressant AdherenceJAMA Psychiatry, 2020
- Voucher-Based Contingency Management is Efficacious but Underutilized in Treating AddictionsPerspectives on Behavior Science, 2019
- The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trialDrug and Alcohol Dependence, 2019
- Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the communityDrug and Alcohol Dependence, 2017
- Financial Reinforcers for Improving Medication Adherence: Findings from a Meta-analysisThe American Journal of Medicine, 2012
- Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: A randomized controlled trialDrug and Alcohol Dependence, 2012